Heart failure & cardiomyopathiesSecondary analysis
Impact of Age on Clinical Outcomes and Response to Serelaxin in Patients with Acute Heart Failure: An Analysis from the RELAX-AHF-2 Trial
- Secondary analysis of the RELAX-AHF-2 randomised trial
- pre-specified clinical outcomes
Authors' conclusion
Elderly patients are at higher risk of short- and long-term CV outcomes after a hospitalization for AHF.
Study context
- Population
- Patients admitted for acute heart failure (AHF) randomised to serelaxin or placebo in RELAX-AHF-2mean age 73.0 ± 11 years
- Participants
- 6,545 patients
- Comparison
- Outcomes and serelaxin treatment effect by age category
- <65n = 1,411
- 65-74n = 1,832
- 75-79n = 1,222
- 80-84n = 1,156
- ≥85n = 924
Primary result
As reported in the abstract
Association of outcomes and serelaxin treatment effect with age categories
All-cause and cardiovascular (CV) death directly associated with age categories
p < 0.001
CV death or HF/renal failure rehospitalization through 180 days directly associated with age categories
p = 0.002
Hospital discharge through day 60 directly associated with age categories
p = 0.013
No clinically significant change in serelaxin treatment effects across age categories for pre-specified endpoints
interaction p > 0.05
Original publication
Impact of Age on Clinical Outcomes and Response to Serelaxin in Patients with Acute Heart Failure: An Analysis from the RELAX-AHF-2 Trial. Eur J Heart Fail. Published 6 September 2024. doi:10.1002/ejhf.3451
Summarised from the published abstract; every number is checked against it